Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Myelofibrosis: unmet needs

Kristen Pettit • 14 Jun 2019
EHA 2019
Myelofibrosis

Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, tells us about the pathology of myelofibrosis, the current FDA approved medication available and the unmet needs patients face. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Kristen Pettit

1:28
Myelofibrosis: LSD1 INHIBITOR IMG-7289
Kristen Pettit • 15 Jun 2019

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals